Prevalence, correlates and pattern of Hepatitis B among antenatal clinic attenders in Yaounde-Cameroon: Is perinatal transmission of HBV neglected in Cameroon?

BMC Pregnancy and Childbirth

Volumn 13, Issue , 2013, Pages 1-10

  Fomulu, Nelson J ^a,b   Morfaw, Frederick L I ^a   Torimiro, Judith N ^a   Nana, Philip ^a   Koh, Mve V ^c   William, Takang ^c  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b Centre Hospitalier et Universitaire de Yaounde   (Cameroon)

^c Laboratory of Systems Biology   (Cameroon)

Author keywords

Hepatitis B; Low resource setting; Pregnancy; Prevalence; Risk factors

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CAMEROON; CROSS-SECTIONAL STUDY; ELISA KIT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREGNANT WOMAN; PRENATAL CARE; PREVALENCE; QUANTITATIVE ANALYSIS; VIRUS INFECTIVITY; VIRUS TRANSMISSION;

EID: 84882687324     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/1471-2393-13-158     Document Type: Article

References (50)

1. Department of Health (UK) Immunization against Infectious Disease - " The Green Book" 2006, 161-184. Hepatitis B, Ref Type: Generic, Department of Health (UK).
2. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, , et al. Centers for Disease Control and Prevention Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR 2008, 57:1-20. Centers for Disease Control and Prevention.
3. Andre F. Hepatitis B: a comprehensive prevention, diagnosis and treatment program - past, present and future. J Gastroenterol Hepatol 2004, 19:1-4. 10.1111/j.1440-1746.2004.03290.x, 14675235.
4. Jonas MM. Hepatitis B, and pregnancy: an underestimated issue. Liver Int 2009, 29(Suppl 1):133-139.
5. World Health Assembly Immunization and Vaccine Quality Expanded programme on immunization. Global advisory group--Part I. Weekly Epidemiological Record 1992, 67(3):11-15. World Health Assembly Immunization and Vaccine Quality.
6. Kane MA. Global status of hepatitis B immunisation. Lancet 1996, 348:696.
7. Lavanchy D. Hepatitis B, virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107. 10.1046/j.1365-2893.2003.00487.x, 14996343.
8. Rumi MA, Begum K, Hassan MS, Hasan SM, Azam MG, Hasan KN, et al. Detection of hepatitis B surface antigen in pregnant women attending a public hospital for delivery: implication for vaccination strategy in Bangladesh. Am J Trop Med Hyg 1998, 59(2):318-322.
9. Shiraki K, Yoshihara N, Kawana T, Yasui H, Sakurai M. Hepatitis B surface antigen and chronic hepatitis in infants born to asymptomatic carrier mothers. Am J Dis Child 1977, 131(6):644-647.
10. Beasley RP, Shiao IS, Wu TC, Hwang LY. Hepatoma in an HBsAg carrier-seven years after perinatal infection. J Pediatr 1982, 101(1):83-84. 10.1016/S0022-3476(82)80190-X, 6283055.
11. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005, 54(RR-16):1-31.
12. Kane MA, Hadler SC, Margolis HS, Maynard JE. Routine prenatal screening for hepatitis B surface antigen. JAMA 1988, 259(3):408-409. 10.1001/jama.1988.03720030068038, 3336167.
13. Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1984, 1(8383):921-926.
14. World Health Organisation (WHO) Hepatitis B vaccines. Wkly Epidemiol Rec 2009, 84:405-420. World Health Organisation (WHO).
15. Chiaramonte M, Stroffolini T, Ngatchu T, Rapicetta M, Lantum D, Kaptue L, et al. Hepatitis B virus infection in Cameroon: a seroepidemiological survey in city school children. J Med Virol 1991, 33(2):95-99. 10.1002/jmv.1890330206, 2051143.
16. Ndumbe PM, Njie TK. Hepatitis A and B infections in Yaounde, Cameroon. Res Virol 1989, 140(3):253-261.
17. Ndumbe PM, Skalsky J, Joller-Jemelka HI. Seroprevalence of hepatitis and HIV infection among rural pregnant women in Cameroon. APMIS 1994, 102(9):662-666.
18. Kfutwah AK, Tejiokem MC, Njouom R. A low proportion of HBeAg among HBsAg-positive pregnant women with known HIV status could suggest low perinatal transmission of HBV in Cameroon. Virol J 2012, 9:62. 10.1186/1743-422X-9-62, 3315739, 22401702.
19. Eke AC, Eke UA, Okafor CI, Ezebialu IU, Ogbuagu C. Prevalence, correlates and pattern of hepatitis B surface antigen in a low resource setting. Virol J 2011, 8:12. 10.1186/1743-422X-8-12, 3027130, 21226907.
20. Biesheuvel CJ, Vergouwe Y, Oudega R, Hoes AW, Grobbee DE, Moons KGM. Advantages of the nested case-control design in diagnostic research. BMC Med Res Methodol 2008, 8(48):1-7. 2244639, 18215293.
21. Noah DN, Njouom R, Bonny A, Pirsou P, Meli J, Biwole-Sida M. HBs antigene prevalence in blood donors and the risk of transfusion of hepatitis b at the central hospital of Yaounde, Cameroon. Open Journal of Gastroenterology 2011, 1(2):23-27.
22. Mbanya DN, Takam D, Ndumbe PM. Serological findings amongst first-time blood donors in Yaounde, Cameroon: is safe donation a reality or a myth?. Transfus Med 2003, 13(5):267-273. 10.1046/j.1365-3148.2003.00453.x, 14617337.
23. Fouelifack FY, Keugoung B, Fouedjio JH, Kouam N, Mendibi S, Dongsta Mabou J. High rates of hepatitis B and C and HIV infections among blood donors in Cameroon: a proposed blood screening algorithm for blood donors in resource-limited settings. Journal of Blood Transfusion 2012, 2012:1-7.
24. Luka SA, Ibrahim MB, Iliya SN. Sero-prevalence of Hepatitis B surface antigen among pregnant women attending Ahmadu Bello University Teaching Hospital, Zaria, Nigeria. Nigerian Journal of Parasitology 2008, 29(1):38-41.
25. Acquaye JK, Mingle JA. Hepatitis B viral markers in Ghanaian pregnant women. West Afr J Med 1994, 13(3):134-137.
26. Itoua-Ngaporo A, Sapoulou MV, Ibara JR, Iloki LH, Denis F. [Prevalence of hepatitis B viral markers in a population of pregnant women in Brazzaville (Congo)]. J Gynecol Obstet Biol Reprod (Paris) 1995, 24(5):534-536.
27. Okoth F, Mbuthia J, Gatheru Z, Murila F, Kanyingi F, Mugo F, et al. Seroprevalence of hepatitis B markers in pregnant women in Kenya. East Afr Med J 2006, 83(9):485-493.
28. Nacro B, Dao B, Dahourou H, Hien F, Charpentier-Gautier L, Meda N, et al. [HBs antigen carrier state in pregnant women in Bobo Dioulasso (Burkina Faso)]. Dakar Med 2000, 45(2):188-190.
29. Madzime S, Adem M, Mahomed K, Woelk GB, Mudzamiri S, Williams MA. Hepatitis B virus infection among pregnant women delivering at Harare Maternity Hospital, Harare Zimbabwe, 1996 to 1997. Cent Afr J Med 1999, 45(8):195-198.
30. Guidozzi F, Schoub BD, Johnson S, Song E. Should pregnant urban south African women be screened for hepatitis B?. S Afr Med J 1993, 83(2):103-105.
31. Bart PA, Jacquier P, Zuber PL, Lavanchy D, Frei PC. Seroprevalence of HBV (anti-HBc, HBsAg and anti-HBs) and HDV infections among 9006 women at delivery. Liver 1996, 16(2):110-116.
32. Descos B, Scotto J, Fayol V, Huet JY, Pichoud C, Hermier M, et al. Anti-HBc screening for the prevention of perinatal transmission of hepatitis B virus in France. Infection 1987, 15(6):434-439. 10.1007/BF01647225, 3436674.
33. Ding Y, Sheng Q, Ma L, Dou X. Chronic HBV infection among pregnant women and their infants in Shenyang, China. Virol J 2013, 10(17):1-5. 3598415, 23279912.
34. Wang Z, Zhang J, Yang H, Li X, Wen S, Guo Y, et al. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 2003, 71(3):360-366. 10.1002/jmv.10493, 12966540.
35. del Canho R, Grosheide PM, Mazel JA, Heijtink RA, Hop WC, Gerards LJ, et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997, 15(15):1624-1630. 10.1016/S0264-410X(97)00080-7, 9364693.
36. Candotti D, Opare-Sem O, Rezvan H, Sarkodie F, Allain JP. Molecular and serological characterization of hepatitis B virus in deferred Ghanaian blood onors with and without elevated alanine aminotransferase. J Viral Hepat 2006, 13(11):715-724. 10.1111/j.1365-2893.2006.00741.x, 17052270.
37. Vazquez-Martinez JL, Coreno-Juarez MO, Montano-Estrada LF, Attlan M, Gomez-Dantes H. Seroprevalence of hepatitis B in pregnant women in Mexico. Salud Publica Mex 2003, 45(3):165-170. 10.1590/S0036-36342003000300005, 12870417.
38. Summers PR, Biswas MK, Pastorek JG, Pernoll ML, Smith LG, Bean BE. The pregnant hepatitis B carrier: evidence favoring comprehensive antepartum screening. Obstet Gynecol 1987, 69(5):701-704.
39. Shahnaz S, Reza B, Seyed-Moayed A. Risk factors for chronic Hepatitis B infection: a case controlled study. Hepat Mon 2005, 5(4):109-115.
40. Ion-Nedelcu N, Mihaileanu C, Dobrescu A. The risks of transmitting viral hepatitis in a section of the city of Bucharest. Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Epidemiol 1989, 34(2):155-162.
41. Nuchprayoon T, Chumnijarakij T. Risk factors for hepatitis B carrier status among blood donors of the National Blood Center, Thai Red Cross Society. Southeast Asian J Trop Med Public Health 1992, 23:246-253.
42. Akani CI, Ojule AC, Opurum HC, Ejilemele AA. Sero-prevalence of hepatitis B surface antigen (HBsAg) in pregnant women in Port Harcourt, Nigeria. Niger Postgrad Med J 2005, 12(4):266-270.
43. Ahmed SD, Cuevas LE, Brabin BJ, Kazembe P, Broadhead R, Verhoeff FH, et al. Seroprevalence of hepatitis B and C and HIV in Malawian pregnant women. J Infect 1998, 37(3):248-251. 10.1016/S0163-4453(98)91983-1, 9892528.
44. Obi CL, Anyiwo CE, Nnatu SN, Agbonlahor DE, Esumeh FI, Karpas A. A comparison of human immunodeficiency virus (HIV) seropositivity and hepatitis B surface antigenemia (HBs Ag) among the same group of apparently healthy pregnant women in Lagos, Nigeria: a preliminary report. Viral Immunol 1993, 6(1):43-47. 10.1089/vim.1993.6.43, 8476507.
45. Dao B, Nacro B, Dahourou H, Meda N, de PP V. [HIV infection and hepatitis B co-infection: survey of prevalence in pregnant women in Bobo Dioulasso, Burkina Faso]. Rev Med Brux 2001, 22(2):83-86.
46. Onakewhor JU, Okonofua FE, Offor E. Maternal and neonatal sero-prevalence of hepatitis B surface antigen (HBsAg) in Benin City, Nigeria. J Obstet Gynaecol 2001, 21(6):583-586. 10.1080/01443610120085528, 12521773.
47. Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, et al. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS 1236 study. J Med Virol 2004, 74(1):34-40. 10.1002/jmv.20143, 15258966.
48. Centers for Disease Control Update on hepatitis B prevention. MMWR 1987, 36:353-360. Centers for Disease Control.
49. Scott RM, Snitbhan R, Bancroft WH, Alter HJ, Tingpalapong M. Experimental transmission of Hepatitis B virus by semen and saliva. J Infect Dis 1980, 142:67-71. 10.1093/infdis/142.1.67, 7400629.
50. World Health Organisation (WHO) Hepatitis B and breastfreeding 1996, Update No. 22, November. Available at http://www.who.int/maternal_child_adolescent/documents/pdfs/hepatitis_b_and_breastfeeding.pdf., World Health Organisation (WHO).